Corporate News for Investors | Ipsen's Latest Financial Updates

Corporate News

Filter

Period

Filter by

recent search

Showing: 105 of 22 Corporate News

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

PARIS, FRANCE; 03 December 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated…



Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

PARIS, FRANCE, 11 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Foreseen Biotechnology (Foreseen) today announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen that is overexpressed…


Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PARIS, FRANCE; BOSTON, U.S., 22 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The…


Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages…


Your dedicated contacts